Abstract
Background The United States’ opioid crisis is worsening, reaching 80,411 deaths in 2021 after a five-fold increase over the past decade. The aim of this study was to comprehensively characterize changes in burden of opioid-overdose mortality in terms of life expectancy reduction and years of life lost between 2019-2021, including differential burden across demographic groups and the contribution of polysubstance use.
Methods Using life tables and counts for all-cause and opioid overdose deaths from the National Center for Health Statistics, we constructed cause-eliminated life tables to estimate mortality by age in the absence of opioid-related deaths. We calculated the loss in life expectancy at birth (LLE) and total years of life lost (YLL) due to opioid overdose deaths by state, sex, racial/ethnic group, and co-involvement of cocaine and psychostimulants.
Findings Opioid-related deaths in the US led to an estimated 3·0 million years of life lost in 2021 (37 years per death), compared to 2·0 million years lost in 2019. Relative to a scenario with no opioid mortality, we estimate that opioid-related deaths reduced life expectancy nationally by 0·65 years in 2021 vs 0·52 years in 2019. This LLE worsened in nearly all demographic groups during the study period: 0·76y to 1y for white men, 0·36y to 0·5y for white women, 0·59y to 0·96y for Black men, 0·27y to 0·43y for Black women, 0·3y to 0·73y for Hispanic men, 0·19y to 0·4y for Hispanic women, 0·62y to 1y for American Indian/Alaska Native (AI/AN) men, 0·43y to 0·9y for (AI/AN) women, and 0·09y to 0·13y for Asian men. Nearly all states experienced an increase in years of life lost (YLL) per capita from 2019-2021, with YLL more than doubling in 10 states. Cocaine or psychostimulants with abuse potential (incl. methamphetamines) were involved in nearly half of all deaths and years of life lost in 2021, with substantial variation in the predominant drug class by state and racial/ethnic group.
Interpretation The burden of opioid-related mortality increased dramatically in the US between 2019-2021, coinciding with the period of the COVID-19 pandemic and the associated disruptions to social, economic, and health systems. Opioid overdose deaths are an important contributor to decreasing US life expectancy, and Black, Hispanic, and indigenous Americans now experience mortality burdens approaching or exceeding white Americans.
Funding None
Evidence before this study The opioid crisis in the US is increasing in severity, with more opioid overdose deaths occurring each year. We searched PubMed and Google Scholar with the terms “opioid epidemic”, “opioid crisis”, “opioid overdoses”, or “opioid mortality” to identify studies evaluating the progression of opioid mortality around the world, and in particular in the US. We used the additional terms “stimulants”, “psychostimulants” or “polysubstance use” to find studies of the increasing polysubstance use, and we used the additional terms “demographic”, or “race and ethnicity” to find studies of the shifting demographics. We used the additional terms “life expectancy” or “life years lost” to find studies estimating these metrics of burden. When finding relevant papers through these searches, we also looked at their citations, as well as the authors’ other publications.
Previous work has established that opioid mortality is a rapidly-changing public health crisis in the US. The years of life lost to opioid overdose deaths have been estimated at various stages of this crisis, and for various subpopulations. One study estimated 1.7 million years of life lost to opioid overdoses in the US in 2016, compared to more recent work finding 2.9 million years lost to unintentional opioid overdoses alone in 2021. Another study estimated that the US population lost 0.36 years in life expectancy as a result of opioid overdose deaths in 2016. However, we could not find estimates of the impact of opioid overdose deaths on US life expectancy or years of life lost in recent years, or comprehensive comparisons of these metrics across demographic groups. We also could not find studies estimating the contributions of the increasing co-involvement of stimulants and opioids to these metrics.
Added value of this study We used all-cause and opioid-related mortality counts to estimate the impact of opioid overdose deaths on life expectancy at birth each year from 2019-2021, using cause-eliminated life tables. We found that opioid-related mortality in 2021 reduced US life expectancy by 0.65 years (compared to 0·52 years in 2019), and resulted in the loss of 3 million years of life (compared to 2 million years lost in 2019) or 37 life years lost per individual death (39 in 2019). We estimated these metrics of burden comprehensively across demographic groups, finding up to 10-fold variation by race/ethnicity and sex or by state. We observed increases in nearly all groups from 2019-2021; nationally, years of life lost increased from 38% among white women to 92% among American Indian/Alaska Native women. The loss in life expectancy at birth was worst amongst AI/AN and white men, at 1 year. We also quantified the contribution of polysubstance use to these metrics of burden, finding that in 2021 polysubstance use of opioids in combination with stimulants was responsible for nearly half the years of life lost to opioid-related deaths.
Implications of all the available evidence Our findings build on prior work to highlight the substantial contribution of opioid-related deaths to the decreases in life expectancy in the US. The young age at which opioid overdose deaths occur - compared to other leading causes of death in the US - amplifies the impact of this crisis on overall life expectancy and life years lost. Our results and previous evidence confirm that the demographics of the opioid crisis have shifted in recent years and that the mortality burden of opioid overdoses is now increasing across all demographic groups in the US. Additionally, the growing co-involvement of stimulants such as methamphetamine and cocaine with opioids is leading to a considerable loss of life. Understanding the mortality burden and the populations at highest risk is crucial for effectively implementing and delivering treatments.
Despite substantial federal and local investments to slow the opioid crisis over the past decade, including expansions to opioid-use-disorder treatments included in COVID-19 response and recovery funding, opioid overdose mortality has only accelerated in recent years. Transformative policy approaches to the opioid crisis are urgently needed to overturn the trends of decreasing life expectancy and to avoid the annual loss of millions of years of life.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally located at: https://wonder.cdc.gov/mcd.html and https://www.cdc.gov/nchs/nvss/life-expectancy.htm
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Analysis and discussion of polysubstance use of opioids in combination with cocaine or psychostimulants with abuse potential was incorporated in the Introduction, Results, and Discussion. Discussion was updated to include more policy implications. All figures were revised: Figure 1 (previously Figure 2) includes two more panels, showing the Years of Life Lost (YLL) by gender and age, and the opioid-related mortality rates by age and polysubstance co-use. Figure 2 shows the YLL and the Loss in Life Expectancy by race/ethnicity and gender during the years 2019-2021, and by state. Figure 3 shows polysubstance use patterns. Supplemental Methods were added to include details on calculations of Years of Life Lost and Loss in Life Expectancy and error estimation. Supplemental Figures 1, 2 and 3 and Supplemental Tables 1, 2, 3, 4, and 5 were added.
Data Availability
Our code is open access on GitHub: https://github.com/annehebert/OpioidsYLL All data produced in the present study are available upon reasonable request to the authors, and are available online at: https://wonder.cdc.gov/mcd-icd10-expanded.html https://www.cdc.gov/nchs/nvss/life-expectancy.htm
https://github.com/annehebert/OpioidsYLL
